A section of ex-Ranbaxy medical representatives (MRs) had challenged in the industrial court in Mumbai Sun Pharma's move to do away with a software application used by erstwhile Ranbaxy MRs for reporting daily activity reports (DAR) and asked them to switch over to a system provided by it.
The industrial court had granted an interim oder in favour of the MRs. It was challenged by the company in the Bombay High Court.
"We have stated very clearly in the court that the company will release the salaries provided these medical representatives (MRs) submit their daily activity reports (DAR) using Target Application," it added.
As on today the migration of all MRs of the erstwhile Ranbaxy to Target Application has been completed and around 94 per cent of them are reporting on it. The balance 6 per cent are refusing to submit their DAR on Target Application, Sun Pharma said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
